<DOC>
	<DOCNO>NCT01710514</DOCNO>
	<brief_summary>The purpose study verify sufficient supplementation luteal hormone administrate FE999913 Vaginal Tablet twice day ( BID ) three time day ( TID ) determine efficacy safety FE999913 Vaginal Tablet Japanese woman undergo fertility treatment IVF-ET ( fresh embryo transfer ) .</brief_summary>
	<brief_title>A Phase III Study FE 999913 Japanese Female Patients Undergoing Fertility Treatment</brief_title>
	<detailed_description />
	<criteria>Premenopausal adult woman age 20 42 year . Early follicular phase ( day 24 ) follicle stimulate hormone ( FSH ) ≤12 IU/L Estradiol &lt; 100 pg/mL . Luteinizing hormone ( LH ) , prolactin ( PRL ) , thyroidstimulating hormone ( TSH ) , within normal limit clinical laboratory test , consider clinically significant investigator within 6 month prior screen . Documented history infertility [ e.g. , unable conceive least one year ( 6 month woman ≥38 year age ) bilateral tubal occlusion absence ] . Transvaginal ultrasound screen ( within 14 day prior screen ) consistent finding adequate Assisted Reproduction Technology ( ART ) respect uterus adnexa ( peripheral reproductive organ ) . At least one cycle fertility medication prior screen . Hysterosalpingography , hysteroscopy , sonohysterogram , transvaginal ultrasound document normal uterine cavity . Consent contraception cycle pituitary regulation perform ( prior start control ovarian stimulation ) . Signed informed consent fertility treatment use FE999913 Vaginal Tablet subject husband thoroughly understood content . Donor oocyte embryo recipient ; gestational surrogate carrier . Undergoing blastomer biopsy experimental ART procedure . Severe hepatic dysfunction disease . Active arterial venous thromboembolism severe thrombophlebitis , history event . Porphyria . Presence clinically relevant systemic disease ( eg , insulindependent diabetes mellitus ) . Past current surgical medical condition judgment Principal Investigator ( Subinvestigator ) may interfere absorption , distribution , metabolism , excretion study drug . Subjects body mass index ( BMI ) &gt; 34 time Screening . Previous IVF ART failure due poor response gonadotropins* . * Defined development ≤2 mature follicles history 2 previous cycle cancellation prior oocyte retrieval due poor response . Presence abnormal uterine bleeding undetermined origin . Current recent ( within past 12 month ) substance abuse , include alcohol . Known suspect breast genital tract cancer . History chemotherapy radiotherapy malignant disorder ( chorionic disease ) . Currently breast feeding , pregnant contraindication pregnancy . Refusal inability comply requirement Protocol reason , include schedule visit clinical laboratory test . Documented intolerance allergy medication use study include investigational medicinal product . Participation experimental drug study within 60 day prior Screening . Use following medication pretreatment treatment phase : hormonal drug product ( use oral contraceptive prior start control ovarian stimulation allow ) , progesterone drug product , hydrocortisone steroid drug product , fertility modifier insulin sensitizer . History recurrent pregnancy loss define 3 spontaneous miscarriage .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>42 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>